Novel Cyano-Artemisinin Dimer ZQJ29 Targets PARP1 to Induce Ferroptosis in Pancreatic Cancer Treatment.
Notably, ZQJ29 is the first reported artemisinin derivative to inhibit PARP1.
Pancreatic Cancer · LIVING RESEARCH LIBRARY
Ongoing Research for Pancreatic Cancer Using Advanced Alternative Medicine
Explore positive published findings by substance, cancer biology, treatment interaction and quality-of-life outcome.
Every entry includes the original study title, year, concise finding and a direct PubMed link.
Call 1.800.923.7878Ask About Your Pancreatic Cancer Case
Tell us the diagnosis, stage, biomarkers, current treatment plan and research questions you want to understand. Our Patient Care Team will follow up personally.
Prefer to speak now?
Call 1.800.923.7878
Living research library · positive published findingsOpen study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed → Open study on PubMed →
Research organized by substance and finding
Browse 20 source-linked studies with the full title, publication year, research focus and a concise finding. Select any linked substance to move directly to its corresponding Sunridge page.
Open study on PubMed →
Epigallocatechin-3-Gallate Decreases Hypoxia-Inducible Factor-1 in Pancreatic Cancer Cells.
When the resulting tumors were analyzed, we found that EGCG decreased tumor-induced HIF-1[Formula: see text] and tumor growth.
Inhibition of glutathione metabolism can limit the development of pancreatic cancer.
Nevertheless, buthionine-sulfoximine also decreases the content of glutathione in normal cells, disrupts the balance between reactive oxygen species and glutathione, and eventually induces cell apoptosis.
Gut microbiome and pancreatic cancer cachexia: An evolving relationship.
Cachexia is characterized by progressive weight loss, muscle wasting, and systemic inflammation and has been linked to poorer outcomes and impairments in quality of life.
Intratumoral microbiota-driven macrophage reprogramming in pancreatic cancer via Blautia metabolite 6-hydroxyhexanoic acid.
Therefore, it is crucial to explore the specific biological processes by which intratumoral microbiome suppresses tumor growth and enhances antitumor immunity.
Leveraging intratumoral probiotics for pancreatic cancer immunotherapy via xenophagy.
This xenophagy-mediated probiotic therapy, termed XenoPro, significantly suppresses tumor growth by presenting B. longum-derived neoantigens and eliciting robust CD4+ T cell activation and tumor-specific cytotoxicity.
Predicting pancreatic cancer survival via the tumor microbiome.
The study reports predicting pancreatic cancer survival via the tumor microbiome.
Probiotics Mitigate High-cholesterol Diet-driven Fatty Liver and Pancreatic Cancer by Restoring Macrophage Homeostasis.
The probiotic formulation LR+F15 significantly suppressed HCCD-induced MASLD and PDAC progression partly through suppressing leaky gut and normalizing peritoneal macrophages' inflammatory properties.
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.
Here, we dissect the role of the tumor microbiota and the immune system in influencing long-term survival.
Upregulation of Lactobacillus spp. in gut microbiota as a novel mechanism for environmental eustress-induced anti-pancreatic cancer effects.
We demonstrated that depletion of gut microbiota with antibiotics abolished EE-induced tumor suppression, while fecal microbiota transplantation (FMT) from EE mice significantly inhibited tumor growth in both subcutaneous and orthotopic PDAC models housed in standard environment.
Quercetin liposomes conjugated with hyaluronidase: An efficient drug delivery system to block pancreatic cancer.
Quercetin (Que), a natural flavonoid, has the ability to inhibit tumor cell growth in a number of cancers; however, its poor water solubility and low bioavailability largely limit its application in cancer therapy.
Resveratrol binds and inhibits transcription factor HIF-1α in pancreatic cancer.
Resveratrol was identified as a natural compound with many biological functions, with anti-inflammatory, antioxidant, and anticancer effects that inhibit the proliferation and progression of PC cells caused by HIF-1α.
Resveratrol inhibits pancreatic cancer proliferation and metastasis by depleting senescent tumor-associated fibroblasts.
Resveratrol is a natural polyphenol known for its multifaceted biological actions, including antioxidative and neuroprotective properties, as well as its potential to inhibit tumor proliferation and migration.
Effects of Alkalization Therapy on Chemotherapy Outcomes in Metastatic or Recurrent Pancreatic Cancer
In a clinical series using an alkaline diet with sodium bicarbonate, patients who reached a higher urine pH had longer median overall survival during chemotherapy.
Anti-Cancer Effect of Sulforaphane in Human Pancreatic Cancer Cells Mia PaCa-2.
The presence of sulforaphane (SFN) in cruciferous vegetables has been found to possess anti-cancer effects in gastric and colon cancers.
Mechanism of sulforaphane in treatment of pancreatic cancer cell based on network pharmacology and in vitro experiments.
Sulforaphane (SFN), a bioactive compound derived from cruciferous vegetables, exhibits anti-cancer properties, though its role in pancreatic cancer is poorly understood.
A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer.
Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have poor 5-year survival.
Pharmacologic ascorbate resistant pancreatic cancer demonstrates enhanced metastatic potential.
Pharmacological ascorbate (P-AscH, high-dose, intravenous, vitamin C), is a pro-drug that generates hydrogen peroxide (H2O2) and is being investigated as a neoadjuvant treatment for pancreatic adenocarcinoma (PDAC).
Pharmacological ascorbate inhibits pancreatic cancer metastases via a peroxide-mediated mechanism.
Phase I studies in pancreatic cancer (PDAC) utilizing P-AscH- have demonstrated increases in progression free survival, suggesting a reduction in metastatic disease burden.
Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer.
The current study demonstrates that pharmacologic ascorbate enhances the cytotoxic effects of ionizing radiation as seen by decreased cell viability and clonogenic survival in all pancreatic cancer cell lines examined, but not in nontumorigenic pancreatic ductal epithelial cells.
No studies match those filters. Clear a filter or try a broader term.